Home › Funds › PSP Research LLC › CLDX
PSP Research LLC position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
PSP Research LLC reported holding 13,000 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$484K, representing 0.26% of its reported portfolio and ranking #22 among its reported holdings. PSP Research LLC has disclosed CLDX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
How PSP Research LLC's CLDX position evolved
PSP Research LLC first disclosed a stake in CLDX in Q4 2025 at 20,368 shares (US$553K). Across 3 filings, PSP Research LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 13,000 shares valued at US$484K. Notable position changes include a 36% trim in Q1 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 20.37K | $553.20K | New |
| Q1 2026 | 13.00K | $412.36K | Reduce |
| Q2 2026 | 13.00K | $483.73K | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 44 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.32M sh · $198.07M · Q2 2026
- Deep Track Capital, LP 2.94M sh · $109.37M · Q2 2026
- Logos Global Management LP 2.10M sh · $78.14M · Q2 2026
- Eversept Partners, LP 1.79M sh · $66.45M · Q2 2026
- Commodore Capital LP 1.35M sh · $50.23M · Q2 2026
- Bellevue Group AG 1.20M sh · $44.65M · Q2 2026
- BAKER BROS. ADVISORS LP 1.18M sh · $44.00M · Q2 2026
- Novo Holdings A/S 1.02M sh · $38.14M · Q2 2026
- Elmind Capital, LP 990.00K sh · $36.84M · Q2 2026
- Foresite Capital Management VI LLC 879.71K sh · $32.73M · Q2 2026
- Affinity Asset Advisors, LLC 700.00K sh · $26.05M · Q2 2026
- Rock Springs Capital Management LP 699.15K sh · $26.02M · Q2 2026